Search
for
Sort by
Research 511–540 of 525
- Elevation of circulating DNAs of disease-associated cytokines in serum cell-free DNA from patients with alopecia areata
- Molecular Mechanisms Affecting Development of Animal Fibers and Some Studies on Goats
- Líquen plano pilar e alopecia frontal fibrosante: correlação dos achados clínicos e dermatoscópicos com o grau de inflamação do exame histopatológico
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- 054 Deep Analysis of CD4+ Trm Cells in Normal and Atopic Dermatitis Human Skin
- <i>IKZF1</i> and Ikaros Overexpression Results in Alopecia Areata‐Like Phenotype in Mice
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- A perspective on predictive markers of alopecia
- 865 Frontal fibrosing alopecia is associated with dysregulation of cholesterol biosynthesis pathways, fibrosis and mast cells
- Biomarkers of alopecia areata disease activity and response to corticosteroid treatment
- Implication of microRNA regulation in para-phenylenediamine-induced cell death and senescence in normal human hair dermal papilla cells
- Pathophysiology of Alopecia Areata in the Pediatric Patient
- <div>Six years of the IP Indian Journal of Clinical and Experimental Dermatology (2019-2025):&nbsp;<span style="font-size: 1rem;">A bibliometric and thematic analysis</span></div>
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- JAK inhibitors in dermatology: The promise of a new drug class
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Under Development JAK Inhibitors for Dermatologic Diseases
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling